Lexeo Therapeutics closes Mantle Therapeutics acquisition

What happened

Lexeo Therapeutics, Inc. (Nasdaq: LXEO) completed its previously announced acquisition of Mantle Therapeutics Inc. on September 29, 2026, according to a Form 8-K filed that day with the Securities and Exchange Commission.

Under the merger agreement, signed September 16, 2026, Lexeo's wholly owned subsidiary Magma Merger Sub Inc. merged into Mantle, with Mantle surviving as a wholly owned Lexeo subsidiary.

At the closing, each outstanding share of Mantle capital stock was converted into the right to receive a share of an upfront purchase price consisting of $5.3 million in cash, subject to adjustments, and $3 million in shares of Lexeo common stock. Mantle's outstanding restricted stock vested and was cancelled for the same consideration. Mantle's outstanding SAFEs were cancelled for the consideration set by their own liquidity-event provisions, and its convertible promissory notes were cancelled upon payment of a payoff amount set under the merger agreement.

The contingent payments

Beyond the closing consideration, the merger agreement provides for contingent payments, which the filing states are not guaranteed and may never become payable. Lexeo would owe a one-time additional cash payment of $1 million only upon the achievement of certain events, and up to $12 million in milestone payments tied to specified development and regulatory milestones for Mantle's product candidates, payable over a milestone term of 12 years. Some of those milestone payments are payable in cash and some in Lexeo common stock, valued using a thirty-day trailing volume-weighted average price as of the date the milestone is achieved.

The filing states that the merger agreement does not require Lexeo to devote any particular level of resources to developing or commercializing Mantle's product candidates beyond a commercially reasonable efforts standard.

The stock issuance

The $3 million in Lexeo shares issued at closing was not registered under the Securities Act of 1933 or any state securities laws. Lexeo issued the shares in reliance on the exemption from registration in Section 4(a)(2) of the Securities Act and/or Regulation D, the private-placement exemptions for transactions not involving a public offering.

Lexeo also filed under Item 3.02 of the 8-K, "Unregistered Sales of Equity Securities," which is the item companies use to disclose this kind of private stock issuance.

Market reaction

Lexeo shares closed at $3.42 on the event date, up 8.92% from the previous close of $3.14, on volume of about 6.56 million shares — roughly 6.73 times the average volume of about 974,000 shares. The filing does not explain the price move, and no source here attributes it to a specific cause.

What this means

An 8-K is the current report a US-listed company files with the SEC when certain specified events occur between its regular quarterly and annual reports. Companies do not file one every day; the form's item numbers say what triggered it. This filing cites Item 2.01, the completion of an acquisition or disposal of assets; Item 3.02, an unregistered sale of equity securities; and Item 9.01, financial statements and exhibits.

A merger structured this way uses a subsidiary as the acquiring vehicle: Lexeo formed Magma Merger Sub Inc., which merged into Mantle so that Mantle became the surviving corporation and a Lexeo subsidiary. That avoids needing Mantle shareholder approval for a transfer of each asset individually — the merger itself moves everything at once.

Two of Mantle's instruments are worth explaining, because they are common in startups and rarely met outside them. A SAFE, or simple agreement for future equity, is a contract under which an investor gives a young company money now in exchange for stock later — typically when the company raises a priced round or is sold. Mantle's SAFEs had "liquidity event" provisions, the clauses that set what holders get when the company is acquired; this merger triggered them. A convertible promissory note is a loan that converts into stock, or in this case gets repaid, on agreed terms. Mantle's were cancelled once the payoff amount was paid, meaning the lenders were cashed out.

The shares paid to Mantle's holders were issued privately, which is why no registration statement was filed. Registration is the process of preparing a public offering with SEC review and a prospectus; selling stock to a small group of sellers in a private deal instead relies on exemptions such as Section 4(a)(2) and Regulation D. The practical consequence is that those shares are restricted securities — the holders generally cannot resell them into the public market immediately without registration or another exemption.

Milestone payments, the up-to-$12 million portion, are earnouts: a buyer pays part of the price only if specified things go right, here development and regulatory events for Mantle's product candidates over 12 years. Paying some milestones in stock at a trailing 30-day volume-weighted average price — an average price weighted by how much traded each day — means the number of shares handed over depends on where Lexeo's stock trades when the milestone is hit, rather than being fixed now. The filing's statement that Lexeo makes no guarantees and is not required to fund beyond commercially reasonable efforts is standard earnout language, and it is the reason the filing itself says these amounts may never be paid.

Lexeo is a clinical-stage biotechnology company — its most recent annual revenue on file is $654,000 for the year ended December 31, 2022 — so acquisitions of product candidates are a way it adds to its pipeline rather than adds to an existing commercial business. The filing does not state Lexeo's rationale for the Mantle deal, does not describe Mantle's product candidates, and does not disclose deal terms beyond the amounts above. It refers to the merger agreement filed as Exhibit 2.1 to the 8-K Lexeo filed September 22, 2026, for the full terms.